David Miller, MD
Urology · Las Vegas, NVNPI 1417487695
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.9%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Boston Scientific at 39.9% of the total. Reporting peaked in 2024 at $5,502 and has fallen 65.4% since, to $1,905 in 2025.
Across 135 payments — averaging $71.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$4K
- Coloplast$3K
- Endo USA, Inc.$414
- Sumitomo Pharma America, Inc.$346
- Procept Biorobotics Corporation$314
- Endo Pharmaceuticals Inc.$248
- plus $1K from 16 others
What the payments were for
- Consulting fees$4505%
- Travel & lodging$3,59237%
- Food & beverage$5,55758%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 32 | $3,833 |
| Coloplast | 33 | $3,359 |
| Endo USA, Inc. | 5 | $414 |
| Sumitomo Pharma America, Inc. | 17 | $346 |
| Procept Biorobotics Corporation | 7 | $314 |
| Endo Pharmaceuticals Inc. | 2 | $248 |
| Urogen Pharma, Inc. | 8 | $212 |
| Dendreon Pharmaceuticals LLC | 5 | $140 |
| AbbVie | 6 | $140 |
| Heron Therapeutics, Inc. | 1 | $122 |
| Calyxo, Inc. | 1 | $86 |
| Johnson & Johnson | 3 | $82 |
| Antares Pharma, Inc. | 4 | $59 |
| Teleflex LLC | 2 | $52 |
| Bayer | 2 | $39 |
| Immunitybio, Inc. | 1 | $31 |
| Merck | 1 | $26 |
| Laborie Medical Technologies Corp. | 1 | $25 |
| AstraZeneca | 1 | $21 |
| Pfizer | 1 | $20 |
| Myriad Genetic Laboratories, Inc. | 1 | $17 |
| 180 Medical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$2,753
- TACTRA$1,109
- XIAFLEX$618
- GENERAL ERECTILE DYSFUNCTION$283
- AMS 700$262
- AquaBeam Robotic System$143
- APONVIE$122
How this compares
$9,599 in reported general payments places this provider in the 65th percentile of 63 urology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 19 | $135 |
Paid to pharmacies, not to this prescriber.
Other urology in Las Vegas
- Vijay GoliLas Vegas$105K
- Joel AbbottLas Vegas$69K
- Victor GrigorievLas Vegas$59K
- Omid LesaniLas Vegas$27K
- Joseph CandelaLas Vegas$24K
- Lawrence NewmanLas Vegas$22K
- Michael VerniLas Vegas$16K
- Mulugeta KassahunLas Vegas$13K
- Jason ZommickLas Vegas$12K
- Ilya GorbachinskyLas Vegas$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.